Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 4,243 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Deficiency Disorder Clear all
Completed Phase 1 Interventional Results available

Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART)

NCT03212989
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Vorinostat, HXTC
Drug · Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 20, 2026, 6:48 PM EDT
Completed Phase 3 Interventional

A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo

NCT00002101
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Ethambutol hydrochloride, Clarithromycin, Rifabutin
Drug
Lead sponsor
Pharmacia
Industry
Eligibility
13 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Phoenix, Arizona • Harbor City, California • Irvine, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 6:48 PM EDT
Not yet recruiting Not applicable Interventional

PrEPwise Pilot Among Black Women in Eastern Virginia

NCT07398482
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Infection
Interventions
PrEPwise, Usual care
Behavioral · Other
Lead sponsor
Boston University
Other
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 20, 2026, 6:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Thymus Transplantation With Immunosuppression #950

NCT00579527
View directory record Official record
Conditions
DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly, Complete DiGeorge Syndrome, Complete Atypical DiGeorge Syndrome
Interventions
Cultured Thymus Tissue for Implantation (CTTI), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Blood Draw, Rabbit anti-thymocyte globulin, Cyclosporine, Tacrolimus, Methylprednisolone or Prednisolone, Daclizumab, Mycophenolate mofetil
Biological · Other · Procedure + 1 more
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 20, 2026, 6:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications

NCT00877591
View directory record Official record
Conditions
Opioid Dependency, HIV Infections
Interventions
Fosamprenavir/Ritonavir, Darunavir/Ritonavir, Rifampin, Rifabutin, Buprenorphine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 20, 2026, 6:48 PM EDT
Completed Not applicable Interventional

Supervised Treadmill Intervention to Reduce Inflammation and Depression Through Exercise in HIV: The STRIDE Pilot Study

NCT06149624
View directory record Official record
Conditions
Depression, Hiv
Interventions
upfront advice to walk, Supervised exercise
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 20, 2026, 6:48 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States

NCT07520188
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), Cervical Cancer, Cervical Precancer
Interventions
Qualitative interviews, Focus groups
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
25 Years and older
Enrollment
3,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 6:48 PM EDT
Completed No phase listed Observational

The Effects of Anti-HIV Drugs on the HIV Virus in HIV-Infected Patients

NCT00006442
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 20, 2026, 6:48 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

NCT01485796
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
Immune Globulin Infusion (Human), 10%, Recombinant human hyaluronidase
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
2 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Irvine, California • Thornton, Colorado • North Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 20, 2026, 6:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals

NCT00885703
View directory record Official record
Conditions
Cryptococcal Meningitis, HIV Infections
Interventions
Fluconazole, Amphotericin B
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 20, 2026, 6:48 PM EDT
Completed No phase listed Observational

Human Papilloma Virus Infection in HIV-Positive Indian Men Who Have Sex With Men

NCT00919997
View directory record Official record
Conditions
Nonneoplastic Condition, Precancerous Condition
Interventions
DNA analysis, polymerase chain reaction, fluorescence activated cell sorting, questionnaire administration, study of socioeconomic and demographic variables, study of high risk factors
Genetic · Other · Procedure
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older · Male only
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 20, 2026, 6:48 PM EDT
Withdrawn Phase 2 Interventional

Sirolimus Prophylaxis for aGVHD in TME SCID

NCT02177760
View directory record Official record
Conditions
Severe Combined Immunodeficiency, Transplacental Maternal Engraftment, Stem Cell Transplant
Interventions
Sirolimus
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Day to 1 Year
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 20, 2026, 6:48 PM EDT
Completed No phase listed Observational

Interventions to Decrease the Risk of Mother-to-Child Transmission of HIV in India

NCT00341796
View directory record Official record
Conditions
HIV-1
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 6:48 PM EDT
Completed Not applicable Interventional

Evaluating Methods to Increase HIV Testing, Access to HIV Care, and HIV Prevention Strategies

NCT01152918
View directory record Official record
Conditions
HIV Infection
Interventions
Linkage-to-Care Component: Financial Incentive (FI), Linkage-to-Care Component: Standard of Care (SOC), Viral Suppression Component: FI, Viral Suppression Component: SOC, Prevention for Positives Component: Counseling and SOC, Prevention for Positives Component: SOC
Behavioral
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
Not listed
Enrollment
18,442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 20, 2026, 6:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel

NCT00561496
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2008 · Synced Oct 20, 2026, 6:48 PM EDT
Completed Phase 1 Interventional

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy

NCT04985760
View directory record Official record
Conditions
HIV Infections
Interventions
Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant
Biological
Lead sponsor
Madhu Chhanda Choudhary
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 20, 2026, 6:48 PM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors

NCT00002213
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Amprenavir, Efavirenz
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Berkeley, California • Los Angeles, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 6:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

NCT02685020
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos.HIV, Clade C gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 20, 2026, 6:48 PM EDT
Completed Phase 1 Interventional

Interactions of HIV Protease Inhibitors and Methadone in HIV-Infected Patients

NCT00000906
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Saquinavir, Methadone hydrochloride
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 20, 2026, 6:48 PM EDT
Not listed Phase 3 Interventional

Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection

NCT00017784
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Valganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Beverly Hills, California • Paramount, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 6:48 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Eliciting Affect in Teens in a Virtual World (Project AVATAR)

NCT02338063
View directory record Official record
Conditions
HIV Infections
Interventions
Virtual Reality, Health Promotion
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
12 Years to 16 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Oct 20, 2026, 6:48 PM EDT
Completed Phase 3 Interventional

A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen

NCT00135343
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanvir/ritonavir + efavirenz
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
15
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlantis, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 20, 2026, 6:48 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects

NCT02154360
View directory record Official record
Conditions
HIV Infection
Interventions
Aprepitant
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 20, 2026, 6:48 PM EDT
Completed Not applicable Interventional

Intervention Targeting Medication Adherence and Methamphetamine Use in HIV Positive Men (ACE)

NCT01122186
View directory record Official record
Conditions
HIV Medication Adherence, Methamphetamine Use, Sexual Risk, Poly-substance Use, HIV Infections
Interventions
Motivational Interviewing + Cognitive Behavioral Skills Training, Education Attention Control
Behavioral
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
18 Years and older · Male only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 20, 2026, 6:48 PM EDT